Investors

Investors

THE 50 Top-Performing Companies ON TSX VENTURE EXCHANGE

Investor Relations

TSXV:NRX | OTCQB:NRXBF | FSE: J90

Transforming Regenerative Medicine

NurExone Biologic is developing exosome-based regenerative therapies for central nervous system injuries.

The Company’s lead therapeutic candidate, ExoPTEN, is being advanced for acute spinal cord injury, with optic nerve injury as an additional preclinical indication.

The investment case is supported by encouraging functional preclinical results, FDA and EMA Orphan Drug Designations for acute spinal cord injury, a completed pre-IND meeting with the FDA, and continued progress in manufacturing, product characterization and regulatory readiness.

In parallel, NurExone is developing exosome production, supply and selected commercial opportunities through Exo-Top, its wholly owned U.S. subsidiary.

Get Investor Updates

Financials & Filings

2026

May 31, 2026

Q1FY26 Interim MD&A

May 31, 2026

Q1FY26 Interim Financial Statments

2025

April 15, 2026

2025 Annual MD&A

April 15, 2026

2025 Audited Annual FS

November 26, 2025

Q3FY25 Interim Financial Statements

November 26, 2025

Q3FY25 Interim MD&A

August 27, 2025

Q2FY25 Interim MD&A

August 27, 2025

Q2FY25 Interim Financial Statements

May 27, 2025

Q1FY25 Interim Financial Statements

May 27, 2025

Q1FY25 Interim MD&A

May 20, 2025

2025 AGM and Special Meeting - Circular

May 20, 2025

2025 AGM and Special Meeting - Notice

May 20, 2025

2025 AGM and Special Meeting – NI Card

2024

April 9, 2025

2024 Audited Annual FS

April 9, 2025

2024 Annual MD&A

November 27, 2024

Q3FY24 Interim MD&A

November 27, 2024

Q3FY24 Interim Financial Statements

August 28, 2024

2023 Annual Information Form

August 27, 2024

Q2FY24 Interim Financial Statements

August 27, 2024

Q2FY24 Interim MD&A

May 29, 2024

Q1FY24 Interim MD&A

May 29, 2024

Q1FY24 Interim Financial Statements

2023

April 2, 2024

2023 Audited Annual MD&A

April 2, 2024

2023 Audited Annual FS

November 24, 2023

Q3 - 2023 Interim MD&A

November 24, 2023

Q3 - 2023 interim FS

August 25, 2023

Q2 - 2023 Interim MD&A

August 25, 2023

Q2 - 2023 interim FS

2022

March 31, 2023

Q4FY22 Annual FS

March 30, 2023

Q4FY22 Annual Information Form

March 29, 2023

Q4FY22 Annual MD&A

November 10, 2022

Management Information Circular

September 30, 2022

Q3-2022 MD&A

September 30, 2022

Q3-2022 interim FS

Latest News

June 30, 2026

NurExone Announces Closing of Non-Brokered Private Placement

June 24, 2026

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

June 1, 2026

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

Events

World SCI Day 2026

From Awareness to Action

September 5, 2026

Boston, USA

The Biotech Event Accelerating Fresh Ideas, Partnerships and Opportunities 2026

September 22-25, 2026

LSX, Boston, USA

Powering Biotech Growth Through Capital and Pharma Partnerships

Sep 22-24, 2026

UK 2027

ADVANCING CELL AND GENE THERAPIES

9 - 10 March, 2027

Past Events

David Lopatie conference centre Weizmann Institute of Science

EVtech

June 1-2, 2026

Suzhou, China

CGCS 2026

May 27-29, 2026

Tel Aviv, Israel

Biomed Israel 2026: The 24th National Life Science & Technology Week

May 12-14, 2026

Vienna, Austria

BioProcess Europe

April 27-30, 2026

Direct Access - Deeper insights

WTR Insights Conference

April 14-15, 2026

London, UK

The Advanced Therapies UK 2026

March 17-18, 2026

Jerusalem, Israel

NanoIL 2026

March 8-10, 2026

San Francisco, CA

JPM Healthcare Conference 2026

January 12-15, 2026

Stockholm, Sweden

Biopharma Innovation Without Boundaries

December 05, 2025

Berlin, Germany

Mind the Tech Berlin 2025

December 2-3, 2025

Mercure Hotel MOA, Berlin, Germany

Transforming Scientific Promise into Therapeutic Progress

1-3 December 2025

מלון דיוויד אינטרקונטיננטל, תל אביב

הכנס השנתי למחקר וניסויים קליניים

November 26, 2025

Berlin, Germany

Falling Walls 2025

November 6-9, 2025

Amsterdam, Netherlands

Exosome Europe - Exosomes: Nature's Nanocarriers, Redefined

November 4-5, 2025

Cambridge, UK

Extracellular Vesicles Forum 2025

October 27-28, 2025

Boston, MA

7th Exosome-Based Therapeutics Development Summit

September 23-25, 2025

Boston, MA

Bio Boston week

September 15-18, 2025

Manchester, NH and Boston, MA

HealthTech Hub - on-site week

September 15-19, 2025

Orlando, Florida

Cell & Gene Therapy Summit

July 7-9, 2025

Scottsdale, Arizona

ASIA - Annual Scientific Meeting 2025

June 2-4, 2025

Nanjing, China

CGCS 2025 - International Cell and Gene Therapy China Summit & Exhibition

May 28-30, 2025

The Felsenstein Medical Research Center, Israel

The 4th Annual meeting of the Israeli Society for Extracellular Vesicles Research (ISREV)

May 22, 2025

Tel Aviv, Israel

BioMed Israel

May 20-22, 2025

Hamburg, Germany

BioProcess International Europe

12-15 May, 2025

Stuttgart, Germany

INVEST Leading trade fair and congress for finance and investments

09 -10 May 2025

NEW ORLEANS, LA

ISCT Annual Meeting 2025

May 7-10, 2025

Vienna, Austria

ISEV Annual Meeting 2025

23-27 April 2025

San Francisco, CA

JPM Healthcare Conference 2025

January 13-16, 2025

Digital Partnering

BIO-Europe: 30 years of facilitating partnerships

November 12–13, 2024

Stockholm, Sweden

BIO Europe ‘In Person’

November 4–6, 2024

Cambridge, UK

Precision EV Forum 2024

23-24 October 2024

Barcelona, Spain

World Orphan Drug Congress Europe 2024

October 22nd – 25th, 2024

Hynes Convention Center Boston, USA

BioProcess International

September 23-26, 2024

Pioneering Israeli Medicine Conference, New York

September 22, 2024

Emerging Growth Conference 73

July 18, 2024

Cambridge, UK

Extracellular Vesicles Forum 2023

10-11 October 2023

Biotech Week Boston 2023!

THE BIOTECH EVENT ACCELERATING FRESH IDEAS, PARTNERSHIPS AND OPPORTUNITIES

September 18-21, 2023

May 21, 2026

A Novel Exosome Platform at the Frontier of CNS Regeneration

By Robert Sassoon-WTR

View Report

April 21, 2026

From Preclinical Promise to Clinical Execution

By Robert Sassoon-WTR

View Report

February 13, 2026

How NRX Stands Out as an Early-Stage Biotech

By Robert Sassoon-WTR

View Report

January 22, 2026

Nurexone Biologic Analyse

By boerse-global.de GmbH

View Report

By Zacks Small Cap Research

View Report

February 20, 2025

NRXBF: US Investors Should Pay Attention

By Zacks Small Cap Research

View Report

2024

FRC provides fee-based coverage

December 11, 2024

Initiating Coverage: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

By Fundamental Research Corp.

View Report

October 2, 2024

Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries

By Zacks Small Cap Research

View Report

July 2024

Action Summary

by Poschevale. Securities. Search.

View Report

5 June 2024

Action Summary

by Litchfield Hills Research LLC

View Report

24 April 2024

Quantitative Equity Research

by Morningstar

View Report

Investor Relations

TSXV:NRX | OTCQB:NRXBF | FSE: J90

Transforming Regenerative Medicine

Get Investor Updates

Financials & Filings

Latest News

NurExone Announces Closing of Non-Brokered Private Placement

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

Events

Presentations​

Latest Presentation

One Pager

Optic NerveOne Pager

Exo-Top One Pager

ISEV TECH

Fact Sheet

AAEV

A Novel Exosome Platform at the Frontier of CNS Regeneration

From Preclinical Promise to Clinical Execution

How NRX Stands Out as an Early-Stage Biotech

Nurexone Biologic Analyse

Analyst Reports

NRXBF: Tremendous Progress Made in Groundbreaking Treatment

NRXBF: Test Results Show Vision Recovery

NRXBF: US Patent Awarded for Cell Technology

NRXBF: Company Treatment Outperforms Industry Standard

NRXBF: Test Results Show Spinal Injury Recovery

NRXBF: Company Remains Disciplined Amid Progress

NRXBF: Critical Year Starts with Company in Good Shape

Poschevale

Tormont50 Growth Report

NRXBF: Tests Confirm Potential for Spinal Cord Injury Recovery

NRXBF: US Investors Should Pay Attention

Initiating Coverage: A Potential Breakthrough in Spinal Cord and Optic Nerve Injury Treatment

Initiating Coverage: Potential Breakthrough Treatment for Spinal Injuries

Action Summary

Action Summary

Quantitative Equity Research

Corporate Governance

Set layout popup

Presentations

Latest
Presentation

Optic Nerve
One Pager

Exo-Top
One Pager